Section 174 R&D Amortization — Advisory Record (TCJA/OBBBA Impact)
Internal Revenue Service
Depends on R&D spend
Critical advisory: R&D expensing rules changed
ADVISORY: §174 is not a credit — it governs the deductibility of research and experimental (R&E) expenditures. The TCJA (2017) eliminated immediate expensing starting January 1, 2022, requiring domestic R&D costs to be amortized over 5 years (15 years for foreign R&D). This was the most consequential TCJA change for tech, biotech, and software companies. The OBBBA (One Big Beautiful Bill Act, signed July 4, 2025) restored immediate expensing for DOMESTIC R&E expenditures incurred after December 31, 2024 and provided retroactive relief for tax years 2022–2024 for qualifying small businesses (≤$31M average annual gross receipts). Foreign R&D remains on 15-year amortization. This record exists to flag the §174 situation to founders who may be unaware of the cash-flow trap and the OBBBA relief.
- Funding type
- Program
- Level
- Federal
- Amount
- Not a credit. §174 governs deductibility of R&E expenditures. Under TCJA (2022–2024): domestic R&D amortized over 5 years (60-month straight-line from midpoint of first year). Under OBBBA restoration (effective for domestic R&E after December 31, 2024): immediate expensing in year incurred. Retroactive relief: qualifying small businesses (≤$31M avg annual gross receipts for 3 prior tax years) may file amended returns for 2022, 2023, and 2024 to deduct previously-amortized domestic R&E expenditures in full.
- Realistic amount
- A SaaS startup with $2M/yr in qualifying domestic R&D wages: under TCJA amortization, only $200K was deductible in Year…
- Deadline
- Ongoing — §174 applies to all domestic R&E expenditures. Retroactive relief for 2022–2024: qualifying small businesses should file amended returns (Form 1040-X for pass-throughs, Form 1120-X for C-corps) or use the §174 election available on the original return for still-open years.
- Status
- active
- States
- Nationwide
- Payment model
- tax offset
Who qualifies
- OBBBA immediate expensing restoration: any US taxpayer (C-corp, S-corp, partnership, sole proprietor) with domestic R&E expenditures paid or incurred after December 31, 2024
- Domestic R&E includes: wages for employees engaged in research and experimentation, supplies used in research, a portion of costs to operate research facilities, and 65% of payments to US contract researchers
- Foreign R&E expenditures (research conducted outside the US) remain on 15-year amortization — OBBBA did NOT restore immediate expensing for foreign R&D
- Retroactive 2022–2024 relief: taxpayer must have ≤$31 million average annual gross receipts for the 3-year period preceding the tax year in question (the small business threshold)
- Retroactive relief: the taxpayer may file an amended return (or make an election on an original return for still-open years) to deduct domestic R&E expenditures in full for 2022, 2023, and 2024
- Note: §174 deductibility and §41 R&D credit qualification overlap but are NOT the same — an expense can qualify under both, neither, or just one. The §174 changes affect the DEDUCTION; §41 credit computation is separate
What it covers
Eligible expenses
- Wages paid to US employees performing, directly supervising, or directly supporting qualified domestic research and experimentation
- Supplies consumed in domestic research activities
- Costs to operate domestic research facilities (utilities, facility overhead allocated to research)
- 65% of payments to US contract researchers performing qualified domestic R&E
- Software development costs meeting the §174 R&E definition (including internal-use software in some circumstances)
Ineligible expenses
- Foreign R&D expenditures — these remain on 15-year amortization under both TCJA and OBBBA (not restored)
- Funded research (amounts for which the taxpayer is entitled to reimbursement from another party regardless of success)
- Quality control testing after commercial production begins
- Market research, advertising, and customer feedback activities
- Acquisition of another's patent, model, production, or process
How to apply
-
1
Identify whether your R&D was amortized under TCJA (2022–2024)
Review your 2022, 2023, and 2024 federal returns. If you had domestic R&E expenditures after January 1, 2022, they were placed on 5-year amortization schedules under the TCJA rule. Identify the amount deferred (the un-amortized carryforward) on each return. This is the pool eligible for retroactive recovery.
~4 hrs
-
2
Determine if you qualify for retroactive small-business relief
Calculate your average annual gross receipts for the 3 tax years preceding 2022, 2023, and 2024 respectively. If each calculation yields ≤$31 million, you qualify. This includes gross receipts of all members of a controlled group (don't look just at your entity in isolation if you're part of a larger structure).
~2 hrs
-
3
File amended returns for 2022–2024 (if qualified and open years remain)
Prepare Form 1040-X (individuals/pass-throughs) or Form 1120-X (C-corps) for each open year. Reverse the prior amortization schedule and claim the full domestic R&E deduction. The refund or credit overpayment can be applied to future estimated taxes. Note: the 3-year amended-return deadline means 2022 calendar-year returns must be amended by approximately April 15, 2026. Act quickly for 2022.
~8 hrs
-
4
Adjust 2025+ tax planning for restored immediate expensing
For tax year 2025 and beyond, domestic R&E expenditures are immediately deductible in the year incurred — revert to pre-TCJA treatment. Update your tax projection model and estimated tax payments accordingly. If you had built amortization schedules into your 2025 projections, remove them.
~3 hrs
-
5
Coordinate §174 expensing with §41 R&D credit calculation
The §41 R&D credit and §174 deduction overlap in scope but are computed differently. Under the §280C election, you can reduce the §41 credit by 21% (for C-corps) and preserve the full §174 deduction. Without the §280C election, you must reduce the §174 deduction by the §41 credit amount. Have your CPA model both scenarios for optimal after-tax position.
~3 hrs
The 2022 amended-return window closes around April 2026 for calendar-year filers. If your business had >$500K in domestic R&D wages in 2022 and qualifies as a small business (≤$31M receipts), filing now could generate a six-figure refund. Don't wait.
Deadline & timing
OBBBA enacted July 4, 2025. Immediate expensing restoration applies to domestic R&E expenditures paid or incurred after December 31, 2024 (i.e., beginning tax year 2025 for calendar-year filers). Retroactive relief for 2022–2024: small businesses with ≤$31M average annual gross receipts may elect to take the full deduction retroactively by filing amended returns. The statute of limitations for amended returns (generally 3 years from original filing) governs which years remain open — consult a CPA promptly if 2022 returns are approaching their amended-return deadline. Foreign R&D expenditures remain on 15-year amortization under both TCJA and OBBBA — not restored.
Programs that stack well
Related programs
Last reviewed 2026. GrantCompass is an independent funding-discovery tool and is not affiliated with any government agency. Always confirm details on the official program page.